- /
- Supported exchanges
- / US
- / OKUR.NASDAQ
OnKure Therapeutics, Inc. (OKUR NASDAQ) stock market data APIs
OnKure Therapeutics, Inc. Financial Data Overview
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with OnKure Therapeutics, Inc. (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get OnKure Therapeutics, Inc. data using free add-ons & libraries
Get OnKure Therapeutics, Inc. Fundamental Data
OnKure Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -61 737 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get OnKure Therapeutics, Inc. Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-08-04
- EPS/Forecast: -0.58
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OnKure Therapeutics, Inc. News
New
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announce...
Biotech Stock Gainers: CODX Extends Rally, SBFM Surges, GOVX Ebola Strategy, RGNX Awaits Catalysts
(RTTNews) - Today's gainers include CODX, which rallied for the third straight day; Akari, on breakthrough clinical data in pancreatic cancer; Sunshine, following regulatory approval for its generic A...
CVS Q1 Earnings Preview: Health Services Likely to Lead Performance
CVS Health CVS is scheduled to report first-quarter 2026 results on May 6, before the market opens. The company posted adjusted earnings per share (EPS) of $1.09 in the last reported quarter, which ...
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Thermo Fisher Scientific TMO is set to release first-quarter 2026 results on April 23, before the market opens. In the last reported quarter, the company posted adjusted earnings per share (EPS) of...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.